Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach.

IF 6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gastric Cancer Pub Date : 2024-11-03 DOI:10.1007/s10120-024-01562-x

Yoshiaki Taniguchi, Daisuke Kiyozawa, Kenichi Kohashi, Shinichiro Kawatoko, Takeo Yamamoto, Takehiro Torisu, Tomoharu Yoshizumi, Masafumi Nakamura, Takanari Kitazono, Yoshinao Oda

{"title":"Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach.","authors":"Yoshiaki Taniguchi, Daisuke Kiyozawa, Kenichi Kohashi, Shinichiro Kawatoko, Takeo Yamamoto, Takehiro Torisu, Tomoharu Yoshizumi, Masafumi Nakamura, Takanari Kitazono, Yoshinao Oda","doi":"10.1007/s10120-024-01562-x","DOIUrl":null,"url":null,"abstract":"Background: Hepatoid adenocarcinoma of the stomach (HAS), a subtype of gastric cancer (GC), includes multiple tumor components, such as enteroblastic and tubular adenocarcinoma components. However, which component mostly contributes to the aggressive behavior of HAS remains unclear. Moreover, the role of tumor-associated macrophages (TAMs) has not been explored in HAS. This study evaluated the clinical significance of the proportion of the hepatoid component within the tumor, CD163 + macrophages, and macrophage colony-stimulating factor-1 (CSF-1) in HAS.Methods: In total, 56 cases of primary HAS were analyzed. In each case, hepatoid (HC), enteroblastic (EC), and tubular (TC) components were identified, and the ratio of HC to the entire tumor (hepatoid component ratio, HCR) was assessed to examine the correlation between HCR and clinicopathological features. Immunohistochemical staining for CD163 and CSF-1 was performed, and differences in immunohistochemical results among the three tumor components were analyzed. In each tumor component, the prognostic impact of CD163 and CSF-1 was examined.Results: A high HCR was associated with worse overall survival (OS). CD163 + TAMs and CSF-1 immunoreactivity score in HC were significantly higher than those in the other components. High infiltration of CD163 + TAMs and a high CSF-1 immunoreactivity score in HC were associated with an aggressive course and worse OS. Multivariate analysis revealed the proportion of HC in HAS as an independent prognostic factor (HR = 3.176, p = 0.006).Conclusions: The HCR and CD163 + TAMs may be useful prognostic predictors, and TAMs may be novel therapeutic targets of HAS.","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":null,"pages":null},"PeriodicalIF":6.0000,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastric Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10120-024-01562-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatoid adenocarcinoma of the stomach (HAS), a subtype of gastric cancer (GC), includes multiple tumor components, such as enteroblastic and tubular adenocarcinoma components. However, which component mostly contributes to the aggressive behavior of HAS remains unclear. Moreover, the role of tumor-associated macrophages (TAMs) has not been explored in HAS. This study evaluated the clinical significance of the proportion of the hepatoid component within the tumor, CD163 + macrophages, and macrophage colony-stimulating factor-1 (CSF-1) in HAS.

Methods: In total, 56 cases of primary HAS were analyzed. In each case, hepatoid (HC), enteroblastic (EC), and tubular (TC) components were identified, and the ratio of HC to the entire tumor (hepatoid component ratio, HCR) was assessed to examine the correlation between HCR and clinicopathological features. Immunohistochemical staining for CD163 and CSF-1 was performed, and differences in immunohistochemical results among the three tumor components were analyzed. In each tumor component, the prognostic impact of CD163 and CSF-1 was examined.

Results: A high HCR was associated with worse overall survival (OS). CD163 + TAMs and CSF-1 immunoreactivity score in HC were significantly higher than those in the other components. High infiltration of CD163 + TAMs and a high CSF-1 immunoreactivity score in HC were associated with an aggressive course and worse OS. Multivariate analysis revealed the proportion of HC in HAS as an independent prognostic factor (HR = 3.176, p = 0.006).

Conclusions: The HCR and CD163 + TAMs may be useful prognostic predictors, and TAMs may be novel therapeutic targets of HAS.

查看原文本刊更多论文

肝样成分的体积和肿瘤内的 M2 巨噬细胞可预测胃肝样腺癌患者的预后。

背景：胃肝样腺癌（HAS）是胃癌（GC）的一种亚型，包括多种肿瘤成分，如肠样腺癌和管状腺癌成分。然而，哪种成分是导致 HAS 侵袭性行为的主要原因仍不清楚。此外，肿瘤相关巨噬细胞（TAMs）在 HAS 中的作用尚未得到探讨。本研究评估了肿瘤内肝样成分的比例、CD163 +巨噬细胞和巨噬细胞集落刺激因子-1（CSF-1）在HAS中的临床意义：方法：共分析了 56 例原发性 HAS。方法：共分析了 56 例原发性 HAS，每例均确定了肝样（HC）、肠样（EC）和管样（TC）成分，并评估了肝样成分与整个肿瘤的比例（肝样成分比，HCR），以研究 HCR 与临床病理特征之间的相关性。对CD163和CSF-1进行免疫组化染色，分析三种肿瘤成分之间免疫组化结果的差异。在每种肿瘤成分中，研究了CD163和CSF-1对预后的影响：结果：高HCR与较差的总生存期（OS）相关。HC中的CD163 + TAMs和CSF-1免疫反应得分明显高于其他成分。HC中CD163 + TAMs的高浸润和CSF-1免疫反应得分高与侵袭性病程和较差的OS有关。多变量分析显示，HAS中HC的比例是一个独立的预后因素（HR = 3.176，P = 0.006）：结论：HCR和CD163 + TAMs可能是有用的预后预测因子，TAMs可能是HAS的新型治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gastric Cancer 医学-胃肠肝病学

CiteScore

14.70

自引率

2.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastric Cancer is an esteemed global forum that focuses on various aspects of gastric cancer research, treatment, and biology worldwide. The journal promotes a diverse range of content, including original articles, case reports, short communications, and technical notes. It also welcomes Letters to the Editor discussing published articles or sharing viewpoints on gastric cancer topics. Review articles are predominantly sought after by the Editor, ensuring comprehensive coverage of the field. With a dedicated and knowledgeable editorial team, the journal is committed to providing exceptional support and ensuring high levels of author satisfaction. In fact, over 90% of published authors have expressed their intent to publish again in our esteemed journal.